28 Aug 2026
We are pleased to share that NICE has recognised another clinical guideline published as part of the Duchenne Care UK national programme that we fund. NICE (the National Institute for Health and Care Excellence) has reviewed Duchenne Care UK’s recommendations on...
30 Apr 2026
We are delighted to share that psychosocial guidelines for Duchenne muscular dystrophy have been published by Duchenne Care UK. We are proud to be a key funder of the psychosocial programme, which is part of a wider, multi‑year national effort by Duchenne Care UK to...
12 Feb 2026
The pychosocial working group gathered around Duchenne Care UK’s newly published education guidelines for teachers. Pictured from left: Duchenne Care UK project coordinator Adam Kerr; Pathfinders advocacy officer Sam Cornelius-Light; consultant child and...
12 Jan 2026
The Duchenne Research Fund is delighted to share that NICE has recognised the respiratory care guidelines that were created and published by the DMD Care UK programme that we fund. This follows NICE’s recognition of DMD Care UK’s cardiac guidelines in...
29 Aug 2025
DMD Care UK has published a report following its national meeting earlier this year, sharing insights into the success of its workshops and knowledge sharing. More than 80 clinical professionals attended in person, and there were more than 170 dial-ins to online...
2 Apr 2025
Pictured: DRF director of operations Sheli Rodney (second from right) with fellow members of the Psychosocial Working Group: disability and education specialist Dr Janet Hoskin, DMD Care UK manager Cathy Turner, Pathfinders Neuromuscular Alliance trustee Benjamin...
10 Dec 2024
New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...
25 Nov 2024
We were invited to join the celebrations for the John Walton Muscular Dystrophy Research Centre’s 10th anniversary in Newcastle. The late Lord John Walton was a pioneering neurologist who made an enormous impact on muscular dystrophy diagnosis and treatment. The...
14 Aug 2024
We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US – Nationwide Children’s Hospital in Columbus, Ohio,...
29 Feb 2024
On 29th February, Rare Disease Day, we were pleased to be part of the 2024 national meeting for DMD Care UK. More than 130 clinicians and 25 patient representatives are now involved in DMD Care UK, giving their time and expertise across no fewer than 13 working groups...